Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

LAVEZZARI

Showing results (31-40 of 78) with videos related to

Pageof 8
Sort By:
Thrombosis Research|November 15, 1987
Indobufen is a potent inhibitor of whole blood aggregation in patients with a high atherosclerotic riskL Mannucci, P Maderna, S Colli, et al.
Bollettino Chimico Farmaceutico|January 1, 1975
[Antisecretory and anti-gastric ulcer activity of a tranquilizing-parasympatholytic combination]V de Pascale, E Lavezzari, F Bamonte, et al.
Bollettino Chimico Farmaceutico|November 1, 1974
[Effect on the capillary permeability of an escin-cyclonamine association]V De Pascale, F Bamonte, E Lavezzari, et al.
Cardiologia (Rome, Italy)|December 1, 1993
[Italian Study on Atrial Fibrillation (SIFA): status report]G Amabile, S Matteoli, F Fattapposta, et al.
Disease Models & Mechanisms|January 8, 2026
Tumor suppressive activities of the cohesin SA1/STAG2 and effects of PARP impairment during Drosophila brain developmentSimona Totaro, Antonella Lettieri, Silvia Castiglioni, et al.
European Journal of Rheumatology and Inflammation|January 1, 1983
A short-term, double-blind comparison between indoprofen and diclofenac in osteoarthritisR Marcolongo, N Giordano, L Mattara, et al.
Thrombosis and Haemostasis|March 1, 1996
A prostacyclin-sparing effect of indobufen vs. aspirinR De Caterina, D Giannessi, W Bernini, et al.
Aspects of Molecular Medicine|July 31, 2023
sgRNAs: A SARS-CoV-2 emerging issueAntonio Mori, Denise Lavezzari, Elena Pomari, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|February 27, 2017
Advancing Value Assessment in the United States: A Multistakeholder PerspectiveCorinna Sorenson, Gabriela Lavezzari, Gregory Daniel, et al.
Circulation|January 1, 1993
Indobufen in the prevention of thromboembolic complications in patients with heart disease. A randomized, placebo-controlled, double-blind studyG Fornaro, P Rossi, P G Mantica, et al.
Pageof 8

Showing results (31-40 of 78) with videos related to

Sort By:
Pageof 8
Thrombosis Research|November 15, 1987
Indobufen is a potent inhibitor of whole blood aggregation in patients with a high atherosclerotic riskL Mannucci, P Maderna, S Colli, et al.
Bollettino Chimico Farmaceutico|January 1, 1975
[Antisecretory and anti-gastric ulcer activity of a tranquilizing-parasympatholytic combination]V de Pascale, E Lavezzari, F Bamonte, et al.
Bollettino Chimico Farmaceutico|November 1, 1974
[Effect on the capillary permeability of an escin-cyclonamine association]V De Pascale, F Bamonte, E Lavezzari, et al.
Cardiologia (Rome, Italy)|December 1, 1993
[Italian Study on Atrial Fibrillation (SIFA): status report]G Amabile, S Matteoli, F Fattapposta, et al.
Disease Models & Mechanisms|January 8, 2026
Tumor suppressive activities of the cohesin SA1/STAG2 and effects of PARP impairment during Drosophila brain developmentSimona Totaro, Antonella Lettieri, Silvia Castiglioni, et al.
European Journal of Rheumatology and Inflammation|January 1, 1983
A short-term, double-blind comparison between indoprofen and diclofenac in osteoarthritisR Marcolongo, N Giordano, L Mattara, et al.
Thrombosis and Haemostasis|March 1, 1996
A prostacyclin-sparing effect of indobufen vs. aspirinR De Caterina, D Giannessi, W Bernini, et al.
Aspects of Molecular Medicine|July 31, 2023
sgRNAs: A SARS-CoV-2 emerging issueAntonio Mori, Denise Lavezzari, Elena Pomari, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|February 27, 2017
Advancing Value Assessment in the United States: A Multistakeholder PerspectiveCorinna Sorenson, Gabriela Lavezzari, Gregory Daniel, et al.
Circulation|January 1, 1993
Indobufen in the prevention of thromboembolic complications in patients with heart disease. A randomized, placebo-controlled, double-blind studyG Fornaro, P Rossi, P G Mantica, et al.
Pageof 8